

Marin H Kollef

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/7502077/publications.pdf](https://exaly.com/author-pdf/7502077/publications.pdf)

Version: 2024-02-01

369
papers

42,545
citations

1911

102
h-index

2358

198
g-index

389
all docs

389
docs citations

389
times ranked

25585
citing authors

#	ARTICLE	IF	CITATIONS
1	Inadequate Antimicrobial Treatment of Infections. Chest, 1999, 115, 462-474.	0.9	1,753
2	The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU Setting. Chest, 2000, 118, 146-155.	0.9	1,657
3	Delaying the Empiric Treatment of <i>Candida</i> Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality. Antimicrobial Agents and Chemotherapy, 2005, 49, 3640-3645.	3.4	1,207
4	Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database. Chest, 2002, 122, 2115-2121.	0.9	1,101
5	Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Critical Care Medicine, 1999, 27, 2609-2615.	0.9	1,043
6	Epidemiology and Outcomes of Health-care-Associated Pneumonia. Chest, 2005, 128, 3854-3862.	0.9	938
7	Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia. Chest, 2002, 122, 262-268.	0.9	920
8	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal, 2017, 50, 1700582.	7.5	877
9	A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. Critical Care Medicine, 1997, 25, 567-574.	0.9	747
10	Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?*. Critical Care Medicine, 2007, 35, 1257-1262.	0.9	726
11	The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections. Drugs, 2007, 67, 351-368.	11.1	725
12	Developing a New, National Approach to Surveillance for Ventilator-Associated Events*. Critical Care Medicine, 2013, 41, 2467-2475.	0.9	635
13	Linezolid vs Vancomycin *. Chest, 2003, 124, 1789-1797.	0.9	592
14	Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients. Clinical Infectious Diseases, 2000, 31, S131-S138.	5.7	561
15	Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Critical Care Medicine, 2001, 29, 1109-1115.	0.9	541
16	Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clinical Infectious Diseases, 2012, 54, 621-629.	5.7	522
17	Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center*. Critical Care Medicine, 2003, 31, 1312-1317.	0.9	513
18	The Prevention of Ventilator-Associated Pneumonia. New England Journal of Medicine, 1999, 340, 627-634.	30.1	508

#	ARTICLE	IF	CITATIONS
19	<i>Pseudomonas aeruginosa</i> Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1306-1311.	3.4	489
20	Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1478.	7.0	480
21	The Importance of Fluid Management in Acute Lung Injury Secondary to Septic Shock. <i>Chest</i> , 2009, 136, 102-109.	0.9	439
22	Beforeâ€“after study of a standardized hospital order set for the management of septic shock*. <i>Critical Care Medicine</i> , 2006, 34, 2707-2713.	0.9	424
23	Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 805.	7.0	416
24	Antibiotic Resistance in the Intensive Care Unit. <i>Annals of Internal Medicine</i> , 2001, 134, 298.	10.2	387
25	Septic Shock Attributed to <i>Candida</i> Infection: Importance of Empiric Therapy and Source Control. <i>Clinical Infectious Diseases</i> , 2012, 54, 1739-1746.	5.7	386
26	A Randomized Clinical Trial Comparing an Extended-Use Hygroscopic Condenser Humidifier With Heated-Water Humidification in Mechanically Ventilated Patients. <i>Chest</i> , 1998, 113, 759-767.	0.9	384
27	The Effect of Late-Onset Ventilator-Associated Pneumonia in Determining Patient Mortality. <i>Chest</i> , 1995, 108, 1655-1662.	0.9	379
28	Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. <i>Critical Care Medicine</i> , 2004, 32, 1396-1405.	0.9	375
29	Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3568-3573.	3.4	370
30	Clinical Characteristics and Treatment Patterns Among Patients With Ventilator-Associated Pneumonia. <i>Chest</i> , 2006, 129, 1210-1218.	0.9	353
31	A Randomized Controlled Trial of an Antibiotic Discontinuation Policy for Clinically Suspected Ventilator-Associated Pneumonia. <i>Chest</i> , 2004, 125, 1791-1799.	0.9	352
32	A Randomized Clinical Trial of Continuous Aspiration of Subglottic Secretions in Cardiac Surgery Patients. <i>Chest</i> , 1999, 116, 1339-1346.	0.9	316
33	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2018, 18, 285-295.	8.9	315
34	Probiotic Prophylaxis of Ventilator-associated Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1058-1064.	6.6	314
35	The Occurrence of Ventilator-Associated Pneumonia in a Community Hospital. <i>Chest</i> , 2001, 120, 555-561.	0.9	313
36	Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 250-256.	2.0	312

#	ARTICLE	IF	CITATIONS
37	A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant <i>Staphylococcus aureus</i> pneumonia. <i>Clinical Therapeutics</i> , 2007, 29, 1107-1115.	2.3	304
38	Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. <i>Intensive Care Medicine</i> , 2004, 30, 388-394.	8.2	302
39	Pneumonia Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Clinical Infectious Diseases</i> , 2008, 46, S378-S385.	5.7	299
40	Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia*. <i>Critical Care Medicine</i> , 2002, 30, 2407-2412.	0.9	289
41	Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2002, 26, 174-181.	2.7	281
42	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 213-225.	8.9	281
43	Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database*. <i>Critical Care Medicine</i> , 2006, 34, 2588-2595.	0.9	274
44	A Comparative Analysis of Patients With Early-Onset vs Late-Onset Nosocomial Pneumonia in the ICU Setting. <i>Chest</i> , 2000, 117, 1434-1442.	0.9	261
45	Risk Factors for Ventilator-Associated Pneumonia: From Epidemiology to Patient Management. <i>Clinical Infectious Diseases</i> , 2004, 38, 1141-1149.	5.7	260
46	Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. <i>Critical Care</i> , 2014, 18, 596.	6.0	256
47	Mechanical Ventilator Weaning Protocols Driven by Nonphysician Health-Care Professionals. <i>Chest</i> , 2001, 120, 454S-463S.	0.9	242
48	Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens. <i>Clinical Infectious Diseases</i> , 2011, 52, 31-40.	5.7	242
49	Predictors of Mortality for Methicillin-Resistant <i>Staphylococcus aureus</i> Health-Care-Associated Pneumonia. <i>Chest</i> , 2006, 130, 947-955.	0.9	239
50	Predictors of 30-Day Mortality and Hospital Costs in Patients With Ventilator-Associated Pneumonia Attributed to Potentially Antibiotic-Resistant Gram-Negative Bacteria. <i>Chest</i> , 2008, 134, 281-287.	0.9	239
51	The Effect of an Education Program on the Incidence of Central Venous Catheter-Associated Bloodstream Infection in a Medical ICU. <i>Chest</i> , 2004, 126, 1612-1618.	0.9	236
52	The Epidemiology and Pathogenesis and Treatment of <i>Pseudomonas aeruginosa</i> Infections: An Update. <i>Drugs</i> , 2021, 81, 2117-2131.	11.1	234
53	Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1299-1311.	8.9	230
54	Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. <i>Clinical Therapeutics</i> , 2003, 25, 980-992.	2.3	227

#	ARTICLE	IF	CITATIONS
55	Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1742-1748.	3.4	223
56	Why Do Physicians Not Follow Evidence-Based Guidelines for Preventing Ventilator-Associated Pneumonia?. <i>Chest</i> , 2002, 122, 656-661.	0.9	222
57	Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis. <i>Critical Care Medicine</i> , 2005, 33, 46-53.	0.9	220
58	Broad-Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front. <i>Clinical Infectious Diseases</i> , 2008, 47, S3-S13.	5.7	218
59	An international multicenter retrospective study of <i>Pseudomonas aeruginosa</i> nosocomial pneumonia: impact of multidrug resistance. <i>Critical Care</i> , 2015, 19, 219.	6.0	214
60	An Educational Intervention to Reduce Ventilator-Associated Pneumonia in an Integrated Health System. <i>Chest</i> , 2004, 125, 2224-2231.	0.9	209
61	Red blood cell transfusion and ventilator-associated pneumonia: A potential link?. <i>Critical Care Medicine</i> , 2004, 32, 666-674.	0.9	204
62	Prediction of Infection Due to Antibiotic-Resistant Bacteria by Select Risk Factors for Health Care-Associated Pneumonia. <i>Archives of Internal Medicine</i> , 2008, 168, 2205.	3.7	196
63	The Safety and Diagnostic Accuracy of Minibronchoalveolar Lavage in Patients with Suspected Ventilator-Associated Pneumonia. <i>Annals of Internal Medicine</i> , 1995, 122, 743.	10.2	194
64	Pleuropulmonary Complications of Panton-Valentine Leukocidin-Positive Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Chest</i> , 2005, 128, 2732-2738.	0.9	181
65	A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. <i>Critical Care</i> , 2012, 16, R218.	6.0	178
66	Silver-Coated Endotracheal Tubes Associated With Reduced Bacterial Burden in the Lungs of Mechanically Ventilated Dogs. <i>Chest</i> , 2002, 121, 863-870.	0.9	175
67	Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay*. <i>Critical Care Medicine</i> , 2011, 39, 46-51.	0.9	165
68	Rationalizing antimicrobial therapy in the ICU: a narrative review. <i>Intensive Care Medicine</i> , 2019, 45, 172-189.	8.2	164
69	Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to <i>Pseudomonas aeruginosa</i> *. <i>Critical Care Medicine</i> , 2014, 42, 2178-2187.	0.9	163
70	Treatment-related risk factors for hospital mortality in <i>Candida</i> bloodstream infections*. <i>Critical Care Medicine</i> , 2008, 36, 2967-2972.	0.9	161
71	Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. <i>Critical Care Medicine</i> , 2000, 28, 3456-3464.	0.9	157
72	Hospital Mortality for Patients With Bacteremia Due to <i>Staphylococcus aureus</i> or <i>Pseudomonas aeruginosa</i> . <i>Chest</i> , 2004, 125, 607-616.	0.9	157

#	ARTICLE	IF	CITATIONS
73	Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections. <i>Clinical Infectious Diseases</i> , 2007, 45, S191-S195.	5.7	157
74	Mechanical Ventilation with or without 7-Day Circuit Changes. <i>Annals of Internal Medicine</i> , 1995, 123, 168.	10.2	152
75	Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia*. <i>Critical Care Medicine</i> , 2003, 31, 2693-2696.	0.9	152
76	Improving Family Communications at the End of Life: Implications for Length of Stay in the Intensive Care Unit and Resource Use. <i>American Journal of Critical Care</i> , 2003, 12, 317-324.	1.7	152
77	Validation of a Clinical Score for Assessing the Risk of Resistant Pathogens in Patients With Pneumonia Presenting to the Emergency Department. <i>Clinical Infectious Diseases</i> , 2012, 54, 193-198.	5.7	151
78	Implementation of a real-time computerized sepsis alert in nonintensive care unit patients*. <i>Critical Care Medicine</i> , 2011, 39, 469-473.	0.9	149
79	Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study*. <i>Critical Care Medicine</i> , 2006, 34, 2766-2772.	0.9	145
80	Methicillin-resistant <i>Staphylococcus aureus</i> sterile-site infection: The importance of appropriate initial antimicrobial treatment*. <i>Critical Care Medicine</i> , 2006, 34, 2069-2074.	0.9	139
81	A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia. <i>Chest</i> , 2017, 151, 1239-1246.	0.9	138
82	Antimicrobial Therapy Escalation and Hospital Mortality Among Patients With Health-Care-Associated Pneumonia. <i>Chest</i> , 2008, 134, 963-968.	0.9	134
83	Methicillin-resistant <i>Staphylococcus aureus</i> prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. <i>Critical Care Medicine</i> , 2006, 34, 700-706.	0.9	131
84	Short- vs Long-Duration Antibiotic Regimens for Ventilator-Associated Pneumonia. <i>Chest</i> , 2013, 144, 1759-1767.	0.9	131
85	Strategies to prevent antimicrobial resistance in the intensive care unit. <i>Critical Care Medicine</i> , 2005, 33, 1845-1853.	0.9	129
86	Fluid balance and cardiac function in septic shock as predictors of hospital mortality. <i>Critical Care</i> , 2013, 17, R246.	6.0	128
87	Duration of Exposure to Antipseudomonal β -Lactam Antibiotics in the Critically Ill and Development of New Resistance. <i>Pharmacotherapy</i> , 2019, 39, 261-270.	2.7	126
88	Secular Trends in Candidemia-Related Hospitalization in the United States, 2000-2005. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 978-980.	2.0	125
89	Appropriate Empirical Antibacterial Therapy for Nosocomial Infections. <i>Drugs</i> , 2003, 63, 2157-2168.	11.1	124
90	Morbidity and cost burden of methicillin-resistant <i>Staphylococcus aureus</i> in early onset ventilator-associated pneumonia. <i>Critical Care</i> , 2006, 10, R97.	6.0	122

#	ARTICLE	IF	CITATIONS
91	Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. <i>Critical Care Medicine</i> , 2007, 35, 1077-1083.	0.9	118
92	A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria*. <i>Critical Care Medicine</i> , 2012, 40, 281-284.	0.9	116
93	Transfusion Practice and Blood Stream Infections in Critically Ill Patients. <i>Chest</i> , 2005, 127, 1722-1728.	0.9	115
94	The Use of Inhaled Prostaglandins in Patients With ARDS. <i>Chest</i> , 2015, 147, 1510-1522.	0.9	113
95	A Randomized Double-Blind Trial of Iseganan in Prevention of Ventilator-associated Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 91-97.	6.6	112
96	Health care-associated pneumonia: identification and initial management in the ED. <i>American Journal of Emergency Medicine</i> , 2008, 26, 1-11.	1.7	112
97	Probiotics for preventing ventilator-associated pneumonia. <i>The Cochrane Library</i> , 2014, 2014, CD009066.	2.8	112
98	Health Care-associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomes Proceedings of the HCAP Summit. <i>Clinical Infectious Diseases</i> , 2008, 46, S296-S334.	5.7	111
99	Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results. <i>Chest</i> , 2005, 128, 2706-2713.	0.9	110
100	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). <i>Intensive Care Medicine</i> , 2020, 46, 245-265.	8.2	109
101	Challenges in severe community-acquired pneumonia: a point-of-view review. <i>Intensive Care Medicine</i> , 2019, 45, 159-171.	8.2	108
102	Economic Burden of Ventilator-Associated Pneumonia Based on Total Resource Utilization. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 509-515.	2.0	106
103	A Prospective Evaluation of Ventilator-Associated Conditions and Infection-Related Ventilator-Associated Conditions. <i>Chest</i> , 2015, 147, 68-81.	0.9	106
104	Nosocomial Infection. <i>Critical Care Medicine</i> , 2021, 49, 169-187.	0.9	106
105	Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. <i>Critical Care Medicine</i> , 2004, 32, 2450-2456.	0.9	105
106	Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis*. <i>Critical Care Medicine</i> , 2009, 37, 819-824.	0.9	105
107	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. <i>Intensive Care Medicine</i> , 2017, 43, 1187-1197.	8.2	105
108	A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes. <i>Chest</i> , 2016, 150, 1008-1014.	0.9	103

#	ARTICLE	IF	CITATIONS
109	Early Palliative Care Consultation in the Medical ICU: A Cluster Randomized Crossover Trial. <i>Critical Care Medicine</i> , 2019, 47, 1707-1715.	0.9	102
110	Selective Digestive Decontamination Should Not Be Routinely Employed*. <i>Chest</i> , 2003, 123, 464S-468S.	0.9	101
111	The importance of appropriate initial antibiotic therapy for hospital-acquired infections. <i>American Journal of Medicine</i> , 2003, 115, 582-584.	1.4	98
112	Re-estimating annual deaths due to multidrug-resistant organism infections. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 112-113.	2.0	97
113	Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality*. <i>Critical Care Medicine</i> , 2018, 46, 736-742.	0.9	96
114	Using the Number Needed to Treat to Assess Appropriate Antimicrobial Therapy as a Determinant of Outcome in Severe Sepsis and Septic Shock*. <i>Critical Care Medicine</i> , 2014, 42, 2342-2349.	0.9	93
115	<i>Staphylococcus aureus</i> Nasal Colonization and Subsequent Infection in Intensive Care Unit Patients: Does Methicillin Resistance Matter?. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 584-591.	2.0	91
116	Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: A multicenter cohort study. <i>Journal of Infection</i> , 2011, 62, 130-135.	3.4	90
117	Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections—Proceedings and Data From the Gram-Negative Resistance Summit. <i>Clinical Infectious Diseases</i> , 2011, 53, S33-S55.	5.7	89
118	Bacterial and fungal superinfections in critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 2071-2074.	8.2	89
119	A Comparison of Culture-Positive and Culture-Negative Health-Care-Associated Pneumonia. <i>Chest</i> , 2010, 137, 1130-1137.	0.9	88
120	Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis*. <i>Critical Care Medicine</i> , 2011, 39, 1859-1865.	0.9	88
121	Secular trends in <i>Acinetobacter baumannii</i> resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. <i>Journal of Hospital Medicine</i> , 2016, 11, 21-26.	1.3	88
122	Implementing quality improvements in the intensive care unit: Ventilator bundle as an example. <i>Critical Care Medicine</i> , 2009, 37, 305-309.	0.9	85
123	Pulmonary infections complicating ARDS. <i>Intensive Care Medicine</i> , 2020, 46, 2168-2183.	8.2	85
124	Ventilator-Associated Tracheobronchitis in a Mixed Surgical and Medical ICU Population. <i>Chest</i> , 2011, 139, 513-518.	0.9	84
125	Use of Adjunctive Aerosolized Antimicrobial Therapy in the Treatment of <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> Ventilator-Associated Pneumonia. <i>Respiratory Care</i> , 2012, 57, 1226-1233.	1.8	84
126	Association between augmented renal clearance and clinical outcomes in patients receiving β -lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 624-630.	3.3	83

#	ARTICLE	IF	CITATIONS
127	Hospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia. <i>Pharmacotherapy</i> , 2010, 30, 361-368.	2.7	82
128	Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit?. <i>Clinical Infectious Diseases</i> , 2006, 43, S82-S88.	5.7	81
129	A randomized trial of real-time automated clinical deterioration alerts sent to a rapid response team. <i>Journal of Hospital Medicine</i> , 2014, 9, 424-429.	1.3	81
130	Initial antimicrobial management of sepsis. <i>Critical Care</i> , 2021, 25, 307.	6.0	78
131	The number of discharge medications predicts thirty-day hospital readmission: a cohort study. <i>BMC Health Services Research</i> , 2015, 15, 282.	2.2	77
132	Diagnostic Implications of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in BAL Fluid of Patients With Pulmonary Infiltrates in the ICU. <i>Chest</i> , 2009, 135, 641-647.	0.9	75
133	Inappropriate therapy for methicillin-resistant <i>Staphylococcus aureus</i> : Resource utilization and cost implications*. <i>Critical Care Medicine</i> , 2008, 36, 2335-2340.	0.9	72
134	Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy026.	0.9	71
135	The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. <i>Critical Care Medicine</i> , 2012, 40, 2016-2021.	0.9	69
136	Timing of antibiotic therapy in the ICU. <i>Critical Care</i> , 2021, 25, 360.	6.0	69
137	Ventilator-Associated Pneumonia in a Multi-Hospital System Differences in Microbiology by Location. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 853-858.	2.0	68
138	A Cost-Benefit Analysis of Gown Use in Controlling Vancomycin-Resistant <i>Enterococcus</i> Transmission Is It Worth the Price?. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 418-424.	2.0	68
139	Cost-Effectiveness Analysis of a Silver-Coated Endotracheal Tube to Reduce the Incidence of Ventilator-Associated Pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 759-763.	2.0	68
140	A risk score for identifying methicillin-resistant <i>Staphylococcus aureus</i> in patients presenting to the hospital with pneumonia. <i>BMC Infectious Diseases</i> , 2013, 13, 268.	3.0	67
141	Use of Hypochlorite Solution to Decrease Rates of <i>Clostridium difficile</i> -Associated Diarrhea. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 205-207.	2.0	65
142	Targeted Fluid Minimization Following Initial Resuscitation in Septic Shock. <i>Chest</i> , 2015, 148, 1462-1469.	0.9	64
143	Using wearable technology to predict health outcomes: a literature review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 1221-1227.	4.6	64
144	Methicillin-resistant <i>Staphylococcus aureus</i> : a new community-acquired pathogen?. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 161-168.	3.1	63

#	ARTICLE	IF	CITATIONS
145	Recognition and prevention of nosocomial pneumonia in the intensive care unit and infection control in mechanical ventilation. <i>Critical Care Medicine</i> , 2010, 38, S352-S362.	0.9	63
146	<i>Clostridium difficile</i> in the ICU. <i>Chest</i> , 2011, 140, 1643-1653.	0.9	63
147	The Alphabet Soup of Pneumonia: CAP, HAP, HCAP, NHAP, and VAP. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 003-009.	2.2	62
148	Methicillin-resistant <i>Staphylococcus aureus</i> nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant <i>Staphylococcus aureus</i> infections requiring antibiotic treatment. <i>Critical Care Medicine</i> , 2010, 38, 1991-1995.	0.9	62
149	Association Between a Silver-Coated Endotracheal Tube and Reduced Mortality in Patients With Ventilator-Associated Pneumonia. <i>Chest</i> , 2010, 137, 1015-1021.	0.9	62
150	Diagnosis of Ventilator-Associated Pneumonia. <i>New England Journal of Medicine</i> , 2006, 355, 2691-2693.	30.1	61
151	Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram-negative bacteremia. <i>Journal of Hospital Medicine</i> , 2011, 6, 405-410.	1.3	60
152	Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation*. <i>Critical Care Medicine</i> , 2010, 38, 1135-1140.	0.9	59
153	Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy*. <i>Critical Care Medicine</i> , 2015, 43, 1580-1586.	0.9	59
154	Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	59
155	The Importance of Early Treatment With Doxycycline in Human Ehrlichiosis. <i>Medicine (United States)</i> , 2008, 87, 53-60.	1.1	58
156	Viruses are prevalent in non-ventilated hospital-acquired pneumonia. <i>Respiratory Medicine</i> , 2017, 122, 76-80.	2.9	58
157	Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review. <i>Intensive Care Medicine</i> , 2016, 42, 1899-1911.	8.2	57
158	Health Care-Associated Infection (HAI): A Critical Appraisal of the Emerging Threat Proceedings of the HAI Summit. <i>Clinical Infectious Diseases</i> , 2008, 47, S55-S99.	5.7	56
159	Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. <i>International Journal of Infectious Diseases</i> , 2011, 15, e545-e550.	3.3	56
160	Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary. <i>Clinical Infectious Diseases</i> , 2013, 57, 1742-1746.	5.7	56
161	Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2030-2037.	3.4	56
162	Probiotics for Preventing and Treating Nosocomial Infections. <i>Chest</i> , 2007, 132, 286-294.	0.9	54

#	ARTICLE	IF	CITATIONS
163	Epidemiology and Outcomes of Hospitalizations with Complicated Skin and Skin-Structure Infections: Implications of Healthcare-Associated Infection Risk Factors. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 1203-1210.	2.0	50
164	Readmission Following Hospitalization for Pneumonia: The Impact of Pneumonia Type and Its Implication for Hospitals. <i>Clinical Infectious Diseases</i> , 2013, 57, 362-367.	5.7	49
165	Epidemiology and Outcomes of Clostridium difficile -Associated Disease Among Patients on Prolonged Acute Mechanical Ventilation. <i>Chest</i> , 2009, 136, 752-758.	0.9	45
166	Aerosolized antibiotics. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 538-544.	3.1	45
167	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , 2018, 4, 00028-2018.	2.7	45
168	Prolonged Infusion Antibiotics for Suspected Gram-Negative Infections in the ICU: A Before-After Study. <i>Annals of Pharmacotherapy</i> , 2013, 47, 170-180.	2.1	44
169	The Burden of Viruses in Pneumonia Associated With Acute Respiratory Failure. <i>Chest</i> , 2018, 154, 84-90.	0.9	44
170	Hospitalizations with healthcare-associated complicated skin and skin structure infections: Impact of inappropriate empiric therapy on outcomes. <i>Journal of Hospital Medicine</i> , 2010, 5, 535-540.	1.3	42
171	Antibiotic Stewardship in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 215-227.	2.2	41
172	Health Care-Associated Pneumonia (HCAP). <i>Medicine (United States)</i> , 2011, 90, 390-395.	1.1	40
173	Predictors of Hospital Mortality for Patients with Severe Sepsis Treated with Drotrecogin alfa (activated). <i>Pharmacotherapy</i> , 2005, 25, 26-34.	2.7	39
174	SMART Approaches for Reducing Nosocomial Infections in the ICU. <i>Chest</i> , 2008, 134, 447-456.	0.9	39
175	Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients With Bloodstream Infection Due to Gram-Negative Bacteria. <i>Clinical Infectious Diseases</i> , 2017, 65, 1607-1614.	5.7	39
176	Treatment of severe skin and soft tissue infections: a review. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 113-119.	3.1	39
177	Predictors of In-Hospital Mortality for Bloodstream Infections Caused by Enterobacter Species or Citrobacter freundii. <i>Pharmacotherapy</i> , 2007, 27, 191-199.	2.7	38
178	The Modified APACHE II Score Outperforms CURB65 Pneumonia Severity Score as a Predictor of 30-Day Mortality in Patients With Methicillin-Resistant Staphylococcus aureus Pneumonia. <i>Chest</i> , 2008, 133, 363-369.	0.9	38
179	Antimicrobial stewardship programs: mandatory for all ICUs. <i>Critical Care</i> , 2012, 16, 179.	6.0	37
180	Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia. <i>Chest</i> , 2019, 155, 53-59.	0.9	37

#	ARTICLE	IF	CITATIONS
181	Candidemia on presentation to the hospital: development and validation of a risk score. <i>Critical Care</i> , 2009, 13, R156.	6.0	36
182	Spot the difference: comparing results of analyses from real patient data and synthetic derivatives. <i>JAMIA Open</i> , 2021, 3, 557-566.	2.1	36
183	<i>Pseudomonas aeruginosa</i> Nosocomial Pneumonia: Impact of Pneumonia Classification. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1190-1197.	2.0	35
184	An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. <i>BMC Infectious Diseases</i> , 2012, 12, 56.	3.0	34
185	Frequent Versus Infrequent Monitoring of Endotracheal Tube Cuff Pressures. <i>Respiratory Care</i> , 2018, 63, 495-501.	1.8	34
186	New antibiotics for community-acquired pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 169-175.	3.1	34
187	Gram-Negative Bacterial Resistance: Evolving Patterns and Treatment Paradigms. <i>Clinical Infectious Diseases</i> , 2005, 40, S85-S88.	5.7	33
188	Providing appropriate antimicrobial therapy in the intensive care unit: Surveillance vs. de-escalation*. <i>Critical Care Medicine</i> , 2006, 34, 903-905.	0.9	33
189	Treatment of gram - positive infections in critically ill patients. <i>BMC Infectious Diseases</i> , 2014, 14, 92.	3.0	33
190	Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship. <i>Critical Care</i> , 2015, 19, 404.	6.0	33
191	Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection. <i>Medicine (United States)</i> , 2018, 97, e12782.	1.1	33
192	Prevention of hospital-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2018, 24, 370-378.	3.4	33
193	Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. <i>Intensive Care Medicine</i> , 2003, 29, 147-149.	8.2	31
194	Diagnostic Utility of Plasma Procalcitonin for Nosocomial Pneumonia in the Intensive Care Unit Setting. <i>Respiratory Care</i> , 2011, 56, 412-419.	1.8	31
195	Predicting Bacteremia among Patients Hospitalized for Skin and Skin-Structure Infections: Derivation and Validation of a Risk Score. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 828-837.	2.0	30
196	Prevention of ventilator-associated pneumonia or ventilator-associated complications. <i>Critical Care Medicine</i> , 2012, 40, 271-277.	0.9	29
197	Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department. <i>BMC Infectious Diseases</i> , 2014, 14, 61.	3.0	29
198	Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy. <i>Clinical Infectious Diseases</i> , 2018, 67, 1455-1462.	5.7	29

#	ARTICLE	IF	CITATIONS
199	Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock. <i>Journal of Critical Care</i> , 2015, 30, 715-720.	2.3	28
200	Monocyte Function and Clinical Outcomes in Febrile and Afebrile Patients With Severe Sepsis. <i>Shock</i> , 2018, 50, 381-387.	2.1	28
201	Culture-negative sepsis. <i>Current Opinion in Critical Care</i> , 2020, 26, 473-477.	3.4	28
202	Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia. <i>Pharmacotherapy</i> , 2006, 26, 204-213.	2.7	27
203	Pneumonia Pathogen Characterization Is an Independent Determinant of Hospital Readmission. <i>Chest</i> , 2015, 148, 103-111.	0.9	27
204	Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 253-263.	2.2	27
205	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 69, 1912-1918.	5.7	27
206	Medical Data Mining for Early Deterioration Warning in General Hospital Wards. , 2011, , .		26
207	Rational Use of Antibiotics in the ICU. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1403.	7.0	26
208	Update on ventilator-associated pneumonia. <i>Current Opinion in Critical Care</i> , 2015, 21, 430-438.	3.4	26
209	Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1451-1454.	2.0	25
210	Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. <i>Critical Care</i> , 2021, 25, 290.	6.0	25
211	Quinolones for Treatment of Nosocomial Pneumonia: A Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2005, 40, S115-S122.	5.7	24
212	Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit. <i>Critical Care</i> , 2005, 9, 459.	6.0	24
213	Prevention of Nosocomial Pneumonia in the Intensive Care Unit: Beyond the Use of Bundles. <i>Surgical Infections</i> , 2011, 12, 211-220.	1.4	24
214	Predictors of Outcome in 216 Subjects With ARDS Treated With Inhaled Epoprostenol. <i>Respiratory Care</i> , 2014, 59, 1178-1185.	1.8	23
215	A Respiratory Therapist Disease Management Program for Subjects Hospitalized With COPD. <i>Respiratory Care</i> , 2017, 62, 1-9.	1.8	23
216	Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study. <i>Critical Care</i> , 2017, 21, 180.	6.0	23

#	ARTICLE	IF	CITATIONS
217	Ventilator-associated Complications, Including Infection-related Complications. <i>Critical Care Clinics</i> , 2013, 29, 33-50.	2.4	22
218	Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.4	22
219	Review of Recent Clinical Trials of Hospitalâ€Acquired Pneumonia and Ventilatorâ€Associated Pneumonia: A Perspective from Academia. <i>Clinical Infectious Diseases</i> , 2010, 51, S29-S35.	5.7	21
220	Reducing the Burden of Acute Respiratory Distress Syndrome. <i>Shock</i> , 2014, 41, 378-387.	2.1	21
221	Identifying Critically Ill Patients at Risk for Inappropriate Antibiotic Therapy. <i>Critical Care Medicine</i> , 2014, 42, 1832-1838.	0.9	21
222	Addition of Vasopressin to Norepinephrine as Independent Predictor of Mortality in Patients with Refractory Septic Shock: An Observational Study. <i>Surgical Infections</i> , 2007, 8, 189-200.	1.4	20
223	Moving Towards Real-Time Antimicrobial Management of Ventilator-Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2007, 44, 388-390.	5.7	19
224	Cluster analysis to define distinct clinical phenotypes among septic patients with bloodstream infections. <i>Medicine (United States)</i> , 2019, 98, e15276.	1.1	19
225	PROPHETIC. <i>Chest</i> , 2020, 158, 2370-2380.	0.9	19
226	New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0231820.	3.4	19
227	Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 12-19.	2.0	18
228	Characteristics of U.S. Acute Care Hospitals That Have Implemented Telemedicine Critical Care. , 2021, 3, e0468.		18
229	Clinical effectiveness of a sedation protocol minimizing benzodiazepine infusions and favoring early dexmedetomidine: a before-after study. <i>Critical Care</i> , 2015, 19, 136.	6.0	17
230	Is Zero Ventilator-Associated Pneumonia Achievable?. <i>Clinics in Chest Medicine</i> , 2018, 39, 809-822.	2.2	17
231	Clinical Effect of Expedited Pathogen Identification and Susceptibility Testing for Gram-Negative Bacteremia and Candidemia by Use of the Accelerate PhenoTM System. <i>Journal of Applied Laboratory Medicine</i> , 2019, 3, 569-579.	1.2	17
232	Management of Severe Sepsis: Integration of Multiple Pharmacologic Interventions. <i>Pharmacotherapy</i> , 2003, 23, 1486-1496.	2.7	16
233	A 50-Year-Old Woman With Abdominal Pain and Respiratory Failure 3 Months After Kidney Transplantation. <i>Chest</i> , 2008, 134, 442-446.	0.9	16
234	What can be expected from antimicrobial de-escalation in the critically ill?. <i>Intensive Care Medicine</i> , 2014, 40, 92-95.	8.2	16

#	ARTICLE	IF	CITATIONS
235	Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 5546-5553.	3.4	16
236	Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	16
237	A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	16
238	Comparison of Sepsis Definitions as Automated Criteria. Critical Care Medicine, 2021, 49, e433-e443.	0.9	16
239	Evaluating the Value of the Respiratory Therapist: Where Is the Evidence? Focus on the Barnes-Jewish Hospital Experience. Respiratory Care, 2017, 62, 1602-1610.	1.8	16
240	Î²-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value. , 2022, 4, e0726.		16
241	Bacteremia Increases the Risk of Death among Patients with Soft-Tissue Infections. Surgical Infections, 2010, 11, 169-176.	1.4	15
242	Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study. Critical Care, 2015, 19, 312.	6.0	15
243	Risk factors for 30-day readmission among patients with culture-positive severe sepsis and septic shock: A retrospective cohort study. Journal of Hospital Medicine, 2015, 10, 678-685.	1.3	15
244	Surveillance versus clinical adjudication: Differences persist with new ventilator-associated event definition. American Journal of Infection Control, 2015, 43, 589-591.	2.5	15
245	Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Critical Care, 2021, 25, 354.	6.0	15
246	Time To Get Serious About Infection Prevention in the ICU. Chest, 2006, 130, 1293-1296.	0.9	14
247	A Pragmatic Machine Learning Model To Predict Carbapenem Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0006321.	3.4	14
248	Microbiological Diagnosis of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1182-1184.	6.6	13
249	Controversies and advances in the management of ventilator associated pneumonia. Expert Review of Respiratory Medicine, 2017, 11, 875-884.	2.5	13
250	Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?. American Journal of Infection Control, 2018, 46, 1092-1096.	2.5	13
251	Racial Disparities in Readmissions Following Initial Hospitalization for Sepsis. Critical Care Medicine, 2021, 49, e258-e268.	0.9	13
252	Azithromycin and survival in <i>Streptococcus pneumoniae</i> pneumonia: a retrospective study. BMJ Open, 2013, 3, e002898.	2.1	12

#	ARTICLE	IF	CITATIONS
253	Novel Approaches to Hasten Detection of Pathogens and Antimicrobial Resistance in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 454-464.	2.2	12
254	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e74-e87.	8.9	12
255	VAT vs VAP. <i>Chest</i> , 2009, 135, 252-255.	0.9	11
256	Risk Factors for Mixed Complicated Skin and Skin Structure Infections To Help Tailor Appropriate Empiric Therapy. <i>Surgical Infections</i> , 2012, 13, 377-382.	1.4	11
257	Determinants of Hospital Mortality Among Patients with Sepsis or Septic Shock Receiving Appropriate Antibiotic Treatment. <i>Current Infectious Disease Reports</i> , 2013, 15, 400-406.	3.2	11
258	Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab508.	0.9	11
259	Prevention of hospital infection. <i>Microbes and Infection</i> , 2005, 7, 268-274.	2.0	10
260	Introduction: Update on the Appropriate Use of Meropenem for the Treatment of Serious Bacterial Infections. <i>Clinical Infectious Diseases</i> , 2008, 47, S1-S2.	5.7	10
261	Oral Decontamination to Prevent Ventilator-Associated Pneumonia. <i>Chest</i> , 2009, 135, 1116-1118.	0.9	10
262	Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators. <i>Critical Care</i> , 2010, 14, R84.	6.0	10
263	Will procalcitonin reduce antibiotic use in intensive care?. <i>Lancet</i> , The, 2010, 375, 435-436.	12.1	10
264	Conservative fluid therapy in septic shock: an example of targeted therapeutic minimization. <i>Critical Care</i> , 2014, 18, 481.	6.0	10
265	Effects of Empiric Antifungal Therapy for Septic Shock on Time to Appropriate Therapy for Candida Infection: A Pilot Study. <i>Clinical Therapeutics</i> , 2014, 36, 1226-1232.	2.3	10
266	Ventilator-associated Pneumonia Prevention. Is It Worth It?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 5-7.	6.6	10
267	A Prospective One-Year Microbiologic Survey of Combined Pneumonia and Respiratory Failure. <i>Surgical Infections</i> , 2017, 18, 827-833.	1.4	10
268	Augmented renal clearance is not a risk factor for mortality in Enterobacteriaceae bloodstream infections treated with appropriate empiric antimicrobials. <i>PLoS ONE</i> , 2017, 12, e0180247.	2.5	10
269	Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.4	10
270	qSOFA score: Predictive validity in Enterobacteriaceae bloodstream infections. <i>Journal of Critical Care</i> , 2018, 43, 143-147.	2.3	10

#	ARTICLE	IF	CITATIONS
271	Pathogen-Negative Sepsis—An Opportunity for Antimicrobial Stewardship. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz397.	0.9	10
272	“Does this patient have” — does this patient at risk for infection with multidrug resistant bacteria? <i>Intensive Care Medicine</i> , 2017, 43, 436-439.	8.2	9
273	COUNTERPOINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? <i>No. Chest</i> , 2017, 151, 740-743.	0.9	9
274	To which extent can we decrease antibiotic duration in critically ill patients?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1215-1223.	3.2	9
275	Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 484-485.	2.0	9
276	Optimizing Therapy for MRSA Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 615-623.	2.2	8
277	Severe hospital-acquired pneumonia: A review for clinicians. <i>Current Infectious Disease Reports</i> , 2009, 11, 349-356.	3.2	8
278	Healthcare-Associated Pneumonia: Approach to Management. <i>Clinics in Chest Medicine</i> , 2011, 32, 507-515.	2.2	8
279	In 2035, will all bacteria be multiresistant? Yes. <i>Intensive Care Medicine</i> , 2016, 42, 2014-2016.	8.2	8
280	Editorial Commentary: Antimicrobial De-escalation: What's in a Name?. <i>Clinical Infectious Diseases</i> , 2016, 62, 1018-1020.	5.7	8
281	Monoclonal antibodies as antibacterial therapies: thinking outside of the box. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1201-1202.	8.9	8
282	Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1166-1177.	3.2	8
283	Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Nasal Colonization Predicts Intensive Care Unit-Acquired MRSA Infections: True Or False?. <i>Surgical Infections</i> , 2010, 11, 497-499.	1.4	7
284	CAP, HCAP, HAP, VAP. <i>Chest</i> , 2017, 152, 909-910.	0.9	7
285	Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia. <i>Clinical Therapeutics</i> , 2019, 41, 2540-2548.	2.3	7
286	Patients Hospitalized With Pneumonia: Determining the Need for Broad-Spectrum Antibiotic Therapy. <i>Clinical Infectious Diseases</i> , 2012, 54, 479-482.	5.7	6
287	Management of Infections with Drug-Resistant Organisms in Critical Care. <i>Clinics in Chest Medicine</i> , 2015, 36, 531-541.	2.2	6
288	ICD-9-CM Coding for Multidrug Resistant Infection Correlates Poorly With Microbiologically Confirmed Multidrug Resistant Infection. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1381-1383.	2.0	6

#	ARTICLE	IF	CITATIONS
289	The most recent concepts for the management of bacterial and fungal infections in ICU. <i>Intensive Care Medicine</i> , 2018, 44, 2000-2003.	8.2	6
290	Postoperative Pneumonia Prevention in Pulmonary Resections: A Feasibility Pilot Study. <i>Annals of Thoracic Surgery</i> , 2019, 107, 262-270.	1.4	6
291	Bloodstream Infections and Delayed Antibiotic Coverage Are Associated With Negative Hospital Outcomes in Hematopoietic Stem Cell Transplant Recipients. <i>Chest</i> , 2020, 158, 1385-1396.	0.9	6
292	Pneumococcal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistance. <i>Respiratory Medicine</i> , 2021, 177, 106307.	2.9	6
293	Race Does Not Impact Sepsis Outcomes When Considering Socioeconomic Factors in Multilevel Modeling. <i>Critical Care Medicine</i> , 2022, 50, 410-417.	0.9	6
294	Early Deterioration Warning for Hospitalized Patients by Mining Clinical Data. <i>International Journal of Knowledge Discovery in Bioinformatics</i> , 2011, 2, 1-20.	0.8	6
295	The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance. <i>Surgical Infections</i> , 2006, 7, 85-99.	1.4	5
296	Clinical Practice Improvement Initiatives. <i>Chest</i> , 2009, 136, 335-338.	0.9	5
297	The Impact of Nighttime Intensivists on Medical Intensive Care Unit Infection-Related Indicators. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 352-354.	2.0	5
298	Prevention of Staphylococcus aureus Ventilator-Associated Pneumonia: Conventional Antibiotics Won't Cut It. <i>Clinical Infectious Diseases</i> , 2017, 64, 1089-1091.	5.7	5
299	Thirty-day hospital readmissions among mechanically ventilated emergency department patients. <i>Emergency Medicine Journal</i> , 2018, 35, 252-256.	2.0	5
300	POINT: Does Persistent or Worsening ARDS Refractory to Optimized Ventilation and Proning Deserve a Trial of Prostacyclin? Yes. <i>Chest</i> , 2019, 155, 662-665.	0.9	5
301	Prevention of Pneumonia in the Hospital Setting. <i>Clinics in Chest Medicine</i> , 2005, 26, 135-142.	2.2	4
302	Health-Care-Associated Pneumonia. <i>Chest</i> , 2009, 135, 594-596.	0.9	4
303	Health Care-Associated Pneumonia. <i>Hospital Practice</i> (1995), 2010, 38, 63-74.	1.0	4
304	Probiotics for Ventilator-Associated Pneumonia. <i>Chest</i> , 2013, 143, 590-592.	0.9	4
305	Use of a Shared Canister Protocol for the Delivery of Metered-Dose Inhalers in Mechanically Ventilated Subjects. <i>Respiratory Care</i> , 2016, 61, 1285-1292.	1.8	4
306	Differences in mortality between infections due to extended-spectrum-beta-lactamase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1138-1139.	2.0	4

#	ARTICLE	IF	CITATIONS
307	Antibiotic Thresholds for Sepsis and Septic Shock. <i>Clinical Infectious Diseases</i> , 2019, 69, 938-940.	5.7	4
308	Impact of Baseline Characteristics on Future Episodes of Bloodstream Infections: Multistate Model in Septic Patients With Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 3103-3109.	5.7	4
309	Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilator-Associated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial. <i>Infectious Diseases and Therapy</i> , 2020, 9, 953-966.	4.1	4
310	Characteristics and outcomes among a hospitalized patient cohort with <i>Streptococcus pneumoniae</i> infection. <i>Medicine (United States)</i> , 2020, 99, e20145.	1.1	4
311	The importance of viruses in ventilator-associated pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 1137-1142.	2.0	4
312	Soluble Triggering Receptor Expressed on Myeloid Cells 1 and the Diagnosis of Ventilator-Associated Pneumonia: Response. <i>Chest</i> , 2009, 136, 320.	0.9	3
313	Increased Mortality in Patients Without Ventilator-Associated Pneumonia: Response. <i>Chest</i> , 2010, 138, 1275.	0.9	3
314	Recognition of Nosocomial Pneumonia in the Intensive Care Unit: Still a Confusing Issue. <i>Respiratory Care</i> , 2011, 56, 1209-1212.	1.8	3
315	Ventilator-Associated Tracheobronchitis and Ventilator-Associated Pneumonia. <i>Chest</i> , 2013, 144, 3-5.	0.9	3
316	Candidemia and non-candidemia related septic shock: are there differences between them?. <i>Intensive Care Medicine</i> , 2014, 40, 1046-1048.	8.2	3
317	Ventilator-Associated Pneumonia Prevention. <i>Chest</i> , 2014, 146, 873-874.	0.9	3
318	Real-time automated clinical deterioration alerts predict thirty-day hospital readmission. <i>Journal of Hospital Medicine</i> , 2016, 11, 768-772.	1.3	3
319	A targeted educational intervention to reduce ventilator-associated complications. <i>American Journal of Infection Control</i> , 2016, 44, 1406-1407.	2.5	3
320	Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill. <i>Clinical Infectious Diseases</i> , 2020, 70, 1520-1521.	5.7	3
321	Reduction in antimicrobial use among medical intensive care unit patients during a cluster randomized crossover trial of palliative care consultation. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 491-492.	2.0	3
322	Next Steps in Pneumonia Severity Scores. <i>Clinical Infectious Diseases</i> , 2021, 72, 950-952.	5.7	3
323	Prospective Nasal Screening for Methicillin-Resistant <i>Staphylococcus aureus</i> in Critically Ill Patients With Suspected Pneumonia. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab578.	0.9	3
324	Classical and Molecular Techniques to Diagnose HAP/VAP. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 219-228.	2.2	3

#	ARTICLE	IF	CITATIONS
325	Impact of Stress Ulcer Prophylaxis Discontinuation Guidance in Mechanically Ventilated, Critically Ill Patients: A Pre-Post Cohort Study. <i>Hospital Pharmacy</i> , 2022, 57, 510-517.	0.9	3
326	The importance of antimicrobial resistance in hospital-acquired and ventilator-associated pneumonia. <i>Current Anaesthesia and Critical Care</i> , 2005, 16, 209-219.	0.3	2
327	Bugging the Bugs: Novel Approaches in the Strategic Management of Resistant <i>Staphylococcus aureus</i> Infections. <i>Clinical Infectious Diseases</i> , 2007, 45, S163-S164.	5.7	2
328	Institutional Perspective on the Impact of Positive Blood Cultures on the Economic and Clinical Outcomes of Patients With Complicated Skin and Skin Structure Infections: Focus on Gram-Positive Infections. <i>Clinical Therapeutics</i> , 2011, 33, 1759-1768.e1.	2.3	2
329	1233A Comparison of National Healthcare Safety Network (NHSN) Ventilator Associated Pneumonia (VAP) and Ventilator Associated Event (VAE) Definitions. <i>Open Forum Infectious Diseases</i> , 2014, 1, S45-S45.	0.9	2
330	Principles of antimicrobial stewardship for bacterial and fungal infections in ICU. <i>Intensive Care Medicine</i> , 2017, 43, 1894-1897.	8.2	2
331	Limitations of Registration Trials for Nosocomial Pneumonia. <i>Clinical Infectious Diseases</i> , 2020, 73, e4549-e4551.	5.7	2
332	Preventive Strategies in VAP: Focus on Silver-Coated Endotracheal Tubes. , 2013, , 531-555.		2
333	The Resuscitation Package in Sepsis. <i>Current Infectious Disease Reports</i> , 2010, 12, 368-373.	3.2	1
334	Ten old antibiotics that will never disappear. <i>Intensive Care Medicine</i> , 2015, 41, 1950-1953.	8.2	1
335	If antibiotics did not exist. <i>Intensive Care Medicine</i> , 2015, 41, 525-527.	8.2	1
336	Rebuttal From Dr Kollef. <i>Chest</i> , 2017, 151, 744-745.	0.9	1
337	Moving the Practice of Respiratory Therapy Forward. <i>Respiratory Care</i> , 2019, 64, 1014-1016.	1.8	1
338	A PRAGMATIC MACHINE LEARNING MODEL TO PREDICT CARBAPENEM RESISTANCE. <i>Chest</i> , 2020, 158, A706.	0.9	1
339	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.4	1
340	Short- Versus Standard-Course Nonmacrolide Antibiotic Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective, Observational Cohort Study. <i>Clinical Therapeutics</i> , 2021, , .	2.3	1
341	Life-Threatening Infections: Pulmonary and Systemic Infections. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 001-002.	2.2	1
342	How to use new antibiotics in the therapy of ventilator-associated pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 140-148.	3.1	1

#	ARTICLE	IF	CITATIONS
343	Mechanical Ventilation Practices and Low Tidal Volume Ventilation in Air Medical Transport Patients: The AIR-VENT Study. <i>Respiratory Care</i> , 2022, 67, 647-656.	1.8	1
344	Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia. <i>Medicine (United States)</i> , 2022, 101, e29159.	1.1	1
345	Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study. <i>JCO Clinical Cancer Informatics</i> , 2023, , .	2.2	1
346	A Persistent Left Lower Lobe Infiltrate and Chronic Cough Following Chest Wounds Sustained in Vietnam Twenty-Four Years Earlier. <i>Military Medicine</i> , 1993, 158, 499-500.	0.9	0
347	Prevention of Antibiotic Resistance in Hospitals. <i>Annals of Internal Medicine</i> , 2002, 136, 173.	10.2	0
348	Correctly scoring infections: CSI in the ICU*. <i>Critical Care Medicine</i> , 2007, 35, 2641-2643.	0.9	0
349	The Flood and Ebb of Septic Shock: Response. <i>Chest</i> , 2009, 136, 1705-1706.	0.9	0
350	Staphylococcal Pneumonia. , 0, , 444-454.		0
351	A magic bullet for sepsis: Getting back to the basics*. <i>Critical Care Medicine</i> , 2010, 38, 733-734.	0.9	0
352	Hospital-acquired pneumonia/ventilator-associated pneumonia prevention: Truth or dare!*. <i>Critical Care Medicine</i> , 2011, 39, 2015-2016.	0.9	0
353	1658C. difficile Recurrence is a Strong Predictor of 30-day Rehospitalization Among ICU Patients. <i>Open Forum Infectious Diseases</i> , 2014, 1, S443-S443.	0.9	0
354	881New Ventilator Associated Event (VAE) Definition: Persistence of Subjective Variability. <i>Open Forum Infectious Diseases</i> , 2014, 1, S253-S253.	0.9	0
355	Reply to MacFadden et al. <i>Clinical Infectious Diseases</i> , 2018, 66, 479-480.	5.7	0
356	1008. Cluster Analysis to Define Distinct Clinical Phenotypes Among Septic Patients With Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, S300-S300.	0.9	0
357	2521 Use of forced air warming devices to induce fever-range hyperthermia in critically ill septic patients. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 50-50.	0.7	0
358	1894. Antimicrobial Stewardship in the Intensive Care Unit: Survey of Critical Care and Infectious Diseases Physicians. <i>Open Forum Infectious Diseases</i> , 2018, 5, S543-S543.	0.9	0
359	872. PROPHETIC: Predicting Pneumonia in Hospitalized Patients in the ICUâ€”A Model and Scoring System. <i>Open Forum Infectious Diseases</i> , 2018, 5, S25-S25.	0.9	0
360	Redefining the Threshold for Broad-Spectrum Antibiotics. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1367-1369.	3.6	0

#	ARTICLE	IF	CITATIONS
361	Rebuttal From Drs Aguilar and Kollef. Chest, 2019, 155, 668-669.	0.9	0
362	Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia – Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 20-21.	8.9	0
363	Microbiologic Failure Despite Clinical Cure in Pneumonia: Cum Hoc and Post Hoc Ergo Propter Hoc. Clinical Infectious Diseases, 2020, 71, 3042-3043.	5.7	0
364	Early Appropriate Empiric Therapy and Antimicrobial De-Escalation. Infectious Disease and Therapy, 2007, , 231-250.	0.0	0
365	2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP). Open Forum Infectious Diseases, 2019, 6, S760-S760.	0.9	0
366	1477. Impact Of Resistance Thresholds On Mortality In Hospital-Acquired And Ventilator-Associated Pneumonia. Open Forum Infectious Diseases, 2020, 7, S739-S740.	0.9	0
367	Lack of pathogen identification influencing antibiotic de-escalation in hospital-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	0
368	Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock. International Journal of Antimicrobial Agents, 2023, 62, 106913.	3.3	0
369	Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study. Clinical Therapeutics, 2024, 46, 338-344.	2.3	0